

REMARKS

Previously, claims 1, 21, 36, 58, 78, 86, 93, 95, 118, 119, 134, 137, 142 and 145 were pending in the application. In the instant amendment, claims 146-163 are added. Applicants note that new claims 146-163 correspond to claims 2-20, respectively, as originally filed. Thus, no new matter is introduced by the present amendment. Entry of the present amendment is respectfully requested.

I. Response To Restriction Requirement

The Examiner has required an election under 35 U.S.C. § 121 of one of the following inventions:

- | | |
|------------|--|
| Group I | Claim 1, drawn to a method of mitigating one or more symptoms associated with chronic consumption of a substance of abuse by a mammal comprising administering an effective amount of an adenosine receptor antagonist, an effective amount of a dopamine receptor antagonist; |
| Group II | Claims 21,134 and 137, drawn to a composition/a kit comprising an effective amount of an adenosine receptor antagonist, an effective amount of a dopamine receptor antagonist; |
| Group III | Claim 36, drawn to a method of mitigating one or more symptoms associated with withdrawal associated with cessation of consumption of a substance of abuse comprising administering to a mammal an effective amount of an adenosine receptor agonist and an effective amount of a dopamine receptor agonist; |
| Group IV | Claims 58,142 and 145, drawn to a composition/kit for mitigating a symptom of withdrawal from a drug of abuse comprising an effective amount of an adenosine receptor agonist and a dopamine receptor agonist; |
| Group V | Claim 78, drawn to a method of mitigating one or more symptoms associated with chronic consumption of a substance of abuse comprising inhibiting expression or activity of a beta/gamma dimer; |
| Group VI | Claim 86, drawn to a method of mitigating consumptive behavior or craving after withdrawal of a substance abuse comprising administering to a mammal an agent that increases effective adenosine levels or activity of an adenosine receptor; |
| Group VII | Claim 93, drawn to a method of mitigating consumptive behavior or craving during chronic consumptive of a substance of abuse comprising administering to a mammal an adenosine receptor antagonist; |
| Group VIII | Claim 95, drawn to a method of screening for an agent that modulates the effect of a substance of abuse on PKA activation in a mammal |

	comprising contacting a mammalian test cell with a test agent and detecting the expression or activity of a beta/gamma dimer or said test cell;
Group IX	Claim 118, drawn to a method of screening for an agent that decouples dopamine receptor activity from an adenosine receptor pathway; and
Group X	Claim 119, drawn to a method of prescreening for an agent that modulates the effect of a substance of abuse on activation in a mammal comprising contacting a beta/gamma dimer or a nucleic acid that encodes a polypeptide comprising a beta/gamma dimer with a test agent and detecting specific binding of said test agent to a beta/gamma dimer.

In response, Applicants elect to prosecute Group I (claim 1), drawn to a method of mitigating one or more symptoms associated with chronic consumption of a substance of abuse by a mammal comprising administering an effective amount of an adenosine receptor antagonist and an effective amount of a dopamine receptor antagonist. Applicants believe that new claims 146-163 read on the elected invention.

Applicants fully reserve the right to prosecute the subject matter of any non-elected inventions in one or more related applications. In addition, Applicants retain the right to petition from the restriction requirement under 37 C.F.R. § 1.144.

CONCLUSION

Applicants respectfully request that the above remarks and amendments be entered and made of record in the file history of the instant application.

No fees are believed to be due with this response. However, pursuant to 37 C.F.R. §1.136 (a)(3), the Commissioner is authorized to charge all required fees, or credit any overpayment, to Jones Day Deposit Account No. 50-3013 (405345-999013).

Respectfully submitted,

Date: August 20, 2009

59,672
Wayne Szeto
(Reg. No.)
For: Rahul Pathak (Reg. No. 42,983)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939